Uncovering Overlooked Insights on Series(ONC)

By Kim Brooks • Monday, August 10 10:45 • Permanent Link

Shares of Pharmaceutical company Series jumped 2.5% today. With many investors piling into ONC without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

Series has moved 20.2% over the last year, and the S&P 500 logged a change of 21.7%
ONC has an average analyst rating of buy and is -17.3% away from its mean target price of $431.7 per share
Its trailing earnings per share (EPS) is $5.61
Series has a trailing 12 month Price to Earnings (P/E) ratio of 63.6 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $10.15 and its forward P/E ratio is 35.2
The company has a Price to Book (P/B) ratio of 8.33 in contrast to the S&P 500's average ratio of 4.74
Series is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
ONC has reported YOY quarterly earnings growth of 166.7% and gross profit margins of 0.9%
The company has a free cash flow of $879.02 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.